Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

721
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
721
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

469
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
469
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

394
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
394
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

624
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
624

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment.

Immunology and cell biology·2026
Same author

Cytokine-induced killer (CIK) Cells-associated transcriptome signature reveals the potential immunomodulatory role of TNFSF14 in clear cell renal cell carcinoma.

Cancer immunology, immunotherapy : CII·2026
Same author

Joint Association of Physical Activity and Prognostic Nutritional Index on Survival in US Cancer Survivors: A Study Based on the NHANES Database.

Cancer medicine·2026
Same author

New Gene Therapy Strategy for β-Thalassemia.

Stem cell reviews and reports·2026
Same author

Participatory development and feasibility study of a digital intervention for detecting and treating bio-psycho-social needs of long-term cancer survivors: study protocol of the DELPHIN study.

BMJ open·2026
Same author

AI-guided additive scoring model for differential diagnosis of primary liver cancer.

JHEP reports : innovation in hepatology·2026

Related Experiment Video

Updated: Apr 15, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K

Lenalidomide in multiple myeloma.

Young Kim1, Ingo G H Schmidt-Wolf

  • 1Medizinische Klinik III, Center for Integrated Oncology (CIO), University of Bonn, Bonn, Germany.

Expert Review of Anticancer Therapy
|April 7, 2015
PubMed
Summary
This summary is machine-generated.

Lenalidomide offers significant clinical benefits for multiple myeloma (MM) treatment, showing improved survival rates. This immunomodulatory agent presents a manageable toxicity profile, making it an attractive option for MM patients.

Keywords:
adverse effectsdrug profileimmunomodulationimmunotherapylenalidomidemyelomapharmacokinetics

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Related Experiment Videos

Last Updated: Apr 15, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma (MM) treatment has advanced with novel agents.
  • Lenalidomide, a second-generation immunomodulatory drug, exhibits antitumor and immune-modulating properties.
  • Autologous stem cell transplantation is often used in combination therapies.

Purpose of the Study:

  • To review current data and research on lenalidomide for multiple myeloma treatment.
  • To highlight the clinical benefits and safety profile of lenalidomide in MM.

Main Methods:

  • Review of Phase III clinical trials data.
  • Analysis of efficacy (overall survival, progression-free survival) and toxicity.

Main Results:

  • Lenalidomide combined with dexamethasone demonstrated significant improvements in overall survival and progression-free survival.
  • These benefits were observed in both induction and maintenance therapy settings.
  • Lenalidomide exhibits a manageable toxicity profile.

Conclusions:

  • Lenalidomide is a valuable therapeutic agent for multiple myeloma.
  • Its efficacy and favorable safety profile support its use in MM treatment regimens.
  • Further research continues to explore lenalidomide's role in MM therapy.